On July 18th, Gelunhui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) recently received the Drug Registration Certificate (Approval Number: 2024S01619, 2024S01620) for Perindopril and Indapamide Tablets (hereinafter referred to as "the pharmaceutical") Perindopril tert-butylamine 4mg, Indapamide 1.25mg, Perindopril tert-butylamine 2mg, Indapamide 0.625mg specifications issued by the National Medical Products Administration. The pharmaceutical has been granted a marketing authorization.
Indications for Perindopril and Indapamide Tablets: For the treatment of primary hypertension in adults. This product is suitable for patients who cannot control their blood pressure with perindopril alone.